Abstract
Evidence-based clinical practice guidelines are systematically developed statements intended to assist practitioners and patients about making and understanding care decisions for specific clinical circumstances. The evidence base should be obtained using an unbiased and transparent process of systematically reviewing and appraising published clinical research, which is then synthesized into recommendations for clinical practice. There is a hierarchy of evidence involved, from meta-analysis or systematic reviews of randomized controlled trials (RCTs), to case-controlled or cohort studies, to expert opinion. Evidence-based guidelines have largely replaced consensus statements, which typically involves a group of experts meeting and producing a series of recommendations based on the consensus of the group at that time. However, these can be prone to bias depending on the opinions of those involved in the process, and often would be based on a limited literature review which might miss key publications, especially if the results are negative.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
International Diabetes Federation (IDF). Glucose control therapy. In: Global guidelines for type 2 diabetes. Brussels: International Diabetes Federation; 2012. p. 55–64.
Inzucchi SE, Bergenstal RM, Buse JB, Dimant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364–79.
Inzucchi SE, Bergenstal RM, Buse JB, Dimant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37 Suppl 1:S61–8.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. Last updated December 2015. www.nice.org.uk/guidance/ng28. Accessed 5 Sept 2016.
Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of glycaemic control in people with type 2 diabetes. In: SIGN 116 management of diabetes. Edinburgh: Scottish Intercollegiate Guidelines Network; 2011. p. 39–55.
Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacological treatment of type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2012;15693:218–31.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–47.
Menéndez Torre E, Lafita Tejedor J, Artola Menéndez S, Milán Núñez-Cortés J, Alonso GarcÃa A, Puig Domingo M, et al. Nefrologia. 2011;31:17–26.
Bundesärztekammer (BÄK) Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes-Langfassung, 1st edition, Version 2. Last updated on September 2013. www.versorgungsleitlinien.de/themen/diabetes2/dm2_Therapie. Accessed 5 Sept 2016.
Japan Diabetes Society. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. www.jds.or.jp/modules/en/index.php?content_id=44. Accessed 5 Sept 2016.
Indian Council of Medical Research. Pharmacological treatment for diabetes. http://icmr.nic.in/guidelines_diabetes/section7.pdf. Accessed 5 Sept 2016.
Lerario AC, Chacra AR, Pimazoni-Netto A, Malerbi D, Gross JL, Oliveira JEP, et al. Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetol Metab Syndr. 2010;2:35. http://dmsjournal.biomedcentral.com/articles/10.1186/1758-5996-2-35. Accessed 5 Sept 2016.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi S, Gunuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: diagnosis and management of type 2 diabetes in adults. Draft for consultation, January 2015. www.nice.org.uk/guidance/gid-cgwave0612/resources/type-2-diabetes-draft-nice-guideline2. Accessed 5 Sept 2016.
O’Hare JP, Miller-Jones D, Hanif W, et al. The new NICE guidelines for type 2 diabetes – a critical analysis. Br J Diabetes. 2015;15:3–7.
Barnett AH. NICE draft type 2 diabetes guidelines: a cause for concern. Lancet Diabetes Endocrinol. 2015;3:403–5.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: diagnosis and management of type 2 diabetes in adults. Draft for consultation, June 2015.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fisher, M. (2017). Guidelines for the Treatment of Type 2 Diabetes Mellitus. In: Essentials of SGLT2 Inhibitors in Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-43296-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-43296-0_3
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-43294-6
Online ISBN: 978-3-319-43296-0
eBook Packages: MedicineMedicine (R0)